Simulations Plus, Inc.
1220 West Avenue J
Tel: 888-266-9294 US and Canada 661-723-7723<br>
310 articles with Simulations Plus, Inc.
User- and collaboration-driven functionality in version 9.7 expands the science of local and systemic exposure
Japanese government organization to train reviewers to efficiently analyze PBPK model submissions
U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology
Simulations Plus, Inc. announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.
Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors.
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite.
New machine learning models and novel analysis methods address customer requests
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).
Conference Call to be on Tuesday, April 9, 2019, at 4:15 PM ET
Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months
New models for in vitro systems lead to improved inputs for GastroPlus® simulations
Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
First quarter net revenues of $7.5 million reflecting 6.6% year over year growth
Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST
Simulations Plus to Present at LD Micro 11th Annual Main Event Investor Conference on December 4, 2018
Simulations Plus, Inc. today announced that Shawn O’Connor, chief executive officer, and John Kneisel, chief financial officer, will present at the 11th Annual LD Micro Main Event investor conference at 9 a.m. PT on Tuesday, December 4, 2018, at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The conference will be held December 4-6, 2018.
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2018 fiscal year (FY18) and fourth quarter (4Q18) ended August 31, 2018.
Simulations Plus, Inc. today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock.
Incorporation of formulation characteristics into the GastroPlus™ mechanistic dermal absorption/PBPK model will inform regulatory decisions
Novel in silico Drug-induced Kidney Injury Model
Enhancements to mechanistic dermal absorption model in GastroPlus™ will target non-pharmaceutical markets